<DOC>
	<DOCNO>NCT00758927</DOCNO>
	<brief_summary>The purpose study verify possible effect OMACOR ( omega-3 fatty acid ) percentage change small dense LDL fraction type 2 diabetic patient combine hyperlipidemia , perform open-label prospective randomize multi-institutional phase IV study .</brief_summary>
	<brief_title>The Effects Omega-3 Fatty Acid ( OMACOR ) Low-density Lipoprotein ( LDL ) Sub-fraction Type 2 Diabetic Patients</brief_title>
	<detailed_description>The main cause mortality type 2 diabetes mellitus cardiovascular disease . Among many risk factor atherosclerosis diabetic patient , LDL ( low density lipoprotein ) cholesterol regard one important modifiable one . Recent research reveal plasma LDL could sub-divided accord size particle large buoyant LDL small dense LDL . Small dense LDL atherogenic . Increased plasma triglyceride presence insulin resistance prove positively correlate well amount small dense LDL diabetic patient . We would like see omega-3 acid ( OMACOR ) widely use clinical practice decrease plasma triglyceride could change amount plasma small dense LDL type 2 diabetic patient combine hyperlipidemia . This trial consist 6 week wash patient already take statin . After , daily 4 gram omega-3 acid ( OMACOR ) administer 10 week . Before administration study drug , measure change amount plasma small dense LDL via ultracentrifuge/non-denaturing polyacrylamide gel electrophoresis follow oil red O coomassie blue stain . As secondary outcome measure , also assess change HDL ( high density lipoprotein ) cholesterol sub-type method .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Agreed inform consent Age 4070 year old Type 2 diabetes mellitus Combined hyperlipidemia Serum triglyceride level 200500 ( mg/dl ) No sudden change glucose lower therapy trial , anticipate Hypersensitivity OMACOR ( Omega3 fatty acid ) Alcoholics Pregnancy Proliferative diabetic retinopathy Patients already take fibrates Enrolled clinical trial recent 3 month Severe ischemic heart disease , liver disease , neurological disease AST/ALT level 2 fold normal reference level Psychiatric disorder adequately control Serum creatinine 2.0 ( mg/dl ) Previous pancreatic surgery Patients maintain regular diet</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>combine hyperlipidemia</keyword>
	<keyword>OMACOR</keyword>
	<keyword>small dense LDL</keyword>
	<keyword>HDL subfraction</keyword>
</DOC>